GoldenGolden
Advanced Search
Excision BioTherapeutics

Excision BioTherapeutics

Excision BioTherapeutics is a company founded in 2015 and headquartered in Philadelphia.

Excision BioTherapeutics is a company that develops CRISPR-based therapies against viral diseases. It develops and manufactures gene-editing therapeutics that fight against the viral genes in humans. Excision BioTherapeutics was founded by Thomas Malcolm.

Timeline

February 17, 2021
Excision BioTherapeutics raises a $60,000,000 venture round from ARTIS Ventures, Adjuvant Capital, Anzu Partners, Cota Capital, GreatPoint Ventures, IndusAge Partners, Loreda Holdings, Norwest Venture Partners, Olive Tree Capital and WRVI Capital.
December 20, 2019
Excision BioTherapeutics raises a $750,000 venture round from Alumni Ventures Group, Benjamin Kong and Gaingels.
September 2017
Excision BioTherapeutics raises a $10,000,000 seed round from ARTIS Ventures.

Funding rounds

Patents

Products

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Annalee Armstrong
September 17, 2021
FierceBiotech
A CRISPR-Cas9 gene editing technology that has shown promise in clearing HIV from mice is headed into human testing. Excision BioTherapeutics will usher the CRISPR-based therapy EBT-101 into clinical trials after the FDA cleared an investigational new drug application.
BioSpace
May 27, 2021
BioSpace
Excision BioTherapeutics ("Excision"), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the addition of infectious disease expert and clinical scientist Sumathi Sivapalasingam, M.D., as Head of Translational Medicine.
BioSpace
May 24, 2021
BioSpace
Excision BioTherapeutics ("Excision"), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the appointment of biotechnology industry development veteran, Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing.
BioSpace
May 5, 2021
BioSpace
Excision BioTherapeutics ("Excision"), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the addition of gene therapy and rare disease expert, Nicole Paulk, Ph.D., to its Scientific Advisory Board (SAB).
BioSpace
May 3, 2021
BioSpace
Excision BioTherapeutics ("Excision"), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the appointment of Christine Silverstein as Chief Financial Officer.
SHOW MORE
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.